Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2021-10-18 Regulatory Filings
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Response to ASX Price and Volume Query 4 pages 350.2KB
Regulatory Filings Classification · 95% confidence The document is a formal response letter from Vectus Biosystems Limited to the ASX Compliance regarding a price query about unusual trading activity in the company's securities. It references ASX Listing Rules 3.1 and 3.1A, which relate to continuous disclosure obligations. The content is focused on compliance with disclosure rules and explanations for recent share price movements, not on financial results, management changes, or other report types. The document is a regulatory communication responding to a market query, typical of a Regulatory Filing (RNS). It is not an announcement of financial results, a report, or a presentation. The length (8899 characters) and content confirm it is a detailed regulatory response rather than a brief announcement or a full report.
2021-10-18 English
Appendix 2A - Issue of Shares 22 pages 554.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Vectus Biosystems Limited regarding the issuance of shares following the conversion of convertible notes and exercise of options. It includes details about the number of shares issued, the conversion price, and compliance with relevant sections of the Corporations Act 2001. The document also contains an Appendix 2A form, which is a standard application for quotation of securities on the Australian Securities Exchange (ASX). This type of document is a formal announcement about share issuance and capital changes, not a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital structure changes and compliance notices related to share issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2021-10-06 English
Update on Phase I Human Trial 1 page 131.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Vectus Biosystems Limited regarding the successful completion of a cohort in a clinical trial phase (Single Ascending Dose segment of a Phase I/Ib trial). It provides details about the trial, its registration number, and company background. There is no financial data, no mention of annual or quarterly results, no regulatory certifications, no voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is a company announcement about a clinical trial milestone, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a general company announcement related to operational progress. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous company announcements that do not fit other categories. The document length is 3408 characters, which is short but contains substantive content rather than just a report publication notice, so it is not RPA. Confidence is high due to clear content and context.
2021-09-06 English
Broker Briefing Investor Webinar 1 page 128.3KB
Regulatory Filings Classification · 90% confidence The document is a short announcement from Vectus Biosystems Limited about an upcoming Broker Briefing Investor Webinar scheduled for 9 September 2021. It provides details about the date, time, presenter, and registration link. There is no financial data, no detailed presentation content, no report attached or referenced as being published, and no regulatory or certification content. The document is clearly an announcement of an investor presentation event rather than the presentation itself or a financial report. Given the short length (1390 characters) and the nature of the content, this fits best as an Investor Presentation announcement. However, since it is only announcing the webinar and not providing the presentation materials, it is not a full Investor Presentation (IP) document. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories better, but since the filing definitions include Investor Presentation (IP) as detailed presentations for investors, and this is an announcement of such a presentation, the closest specific category is IP with moderate confidence. However, per the MENU VS MEAL rule, announcements of presentations are not the presentations themselves, so the correct classification is Regulatory Filings (RNS).
2021-09-06 English
Preliminary Final Report - Appendix 4E 1 page 93.6K
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report for the financial year ended 30 June 2021' and contains financial results for the year ended 30 June 2021, including revenues, losses, net tangible asset backing, and cash balances. It references the Corporations Act 2001 and states that the report is based on audited accounts. It also mentions that the audited Annual Financial Report accompanies this announcement, indicating this document is a summary or preliminary final report rather than the full annual report itself. Appendix 4E is a regulatory filing used in Australia to announce preliminary final results before the full annual report is released. The document length is 3030 characters, which is relatively short and consistent with a summary announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a preliminary announcement of financial results and not the full Annual Report (10-K) or a detailed Interim Report (IR).
2021-08-30 English
Full Year Statutory Accounts 51 pages 2.3MB
Regulatory Filings
2021-08-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.